Current System of Overseeing Drug Trials in Developing Countries by the FDA Is Dangerous

5Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Clinical research used to substantiate Food and Drug Administration (FDA) drug approval is increasingly being conducted overseas. One of the enticements to move overseas is unequal oversight by the FDA, and these differences can result in poor quality research and human subject risk. Downstream, patients, clinicians, and payers of health care can be harmed by inaccuracies in the new drug approval process. The need of the hour is to bridge the gap in the standards by ensuring that the investigators in the developing countries adhere to the same quality standards as the domestic investigators.

Author supplied keywords

Cite

CITATION STYLE

APA

White, C. M. (2020, September 1). Current System of Overseeing Drug Trials in Developing Countries by the FDA Is Dangerous. Annals of Pharmacotherapy. SAGE Publications Inc. https://doi.org/10.1177/1060028020906484

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free